ArticleMolecular imaging and biology2017
Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF
Article in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Reproducibility and repeatability of 18F-(2S, 4R)-4-fluoroglutamine PET imaging in preclinical oncology models.PloS one · 2025Article
- Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.Tomography (Ann Arbor, Mich.) · 2023Review
- [Molecular imaging · 2022Article
- First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer.Cold Spring Harbor perspectives in medicine · 2021Review
- ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation.Cancers · 2021Review
- A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapy.Immunotherapy advances · 2021Review
- Correlation Between Prognostic BiomarkerFrontiers in oncology · 2021Article
- Natural Products and Derivatives Targeting at Cancer Energy Metabolism: A Potential Treatment Strategy.Current medical science · 2020Review
- Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[Molecular imaging and biology · 2019Article
- Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.Nature medicine · 2018Article
- An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.American journal of cancer research · 2018Article
- Imaging Cancer Metabolism.Biomolecules & therapeutics · 2018Review
- Glutamine Metabolism in Cancer: Understanding the Heterogeneity.Trends in cancer · 2017Review
- PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeThis study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake may reflect critical processes in oncology. Approximately, 10 % of patients with colorectal cancer (CRC) express BRAF PROCEDURES: Tumor microarrays from patients with primary human colon cancers (n = 115) and CRC liver metastases (n = 111) were used to evaluate the prevalence of ASCT2, the primary glutamine transporter in oncology, by immunohistochemistry. Subsequently, 4-[
resultsApproximately 70 % of primary colon cancers and 53 % of metastases exhibited positive ASCT2 immunoreactivity, suggesting that [
conclusions4-[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.